Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

Maria Apicella, Elisa Giannoni, Stephany Fiore, Karin Johanna Ferrari, Daniel Fernández-Pérez, Claudio Isella, Carlotta Granchi, Filippo Minutolo, Antonino Sottile, Paolo Maria Comoglio, Enzo Medico, Filippo Pietrantonio, Marco Volante, Diego Pasini, Paola Chiarugi, Silvia Giordano, Simona Corso

Research output: Contribution to journalArticlepeer-review

Abstract

The tumor microenvironment shapes cancer progression. Apicella et al. now show that cancer-associated fibroblasts play an active metabolic role in adaptive cancer drug resistance to tyrosine kinase inhibitors (TKIs). Targeting the non-cell-autonomous lactate/HGF/MET-signaling axis abrogated acquired TKI resistance in cancer models.

Original languageEnglish
Pages (from-to)848-865.e6
JournalCell Metabolism
Volume28
Issue number6
DOIs
Publication statusPublished - Dec 4 2018

Keywords

  • CAFs
  • EGFR
  • HGF/MET
  • lactate
  • LDH
  • MCT1/4
  • resistance
  • targeted therapy
  • tumor metabolism
  • tumor microenvironment

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies'. Together they form a unique fingerprint.

Cite this